PL371264A1 - Sposób leczenia chorób kości - Google Patents

Sposób leczenia chorób kości

Info

Publication number
PL371264A1
PL371264A1 PL02371264A PL37126402A PL371264A1 PL 371264 A1 PL371264 A1 PL 371264A1 PL 02371264 A PL02371264 A PL 02371264A PL 37126402 A PL37126402 A PL 37126402A PL 371264 A1 PL371264 A1 PL 371264A1
Authority
PL
Poland
Prior art keywords
treatment
bone disorders
risedronate
polymorph
solvate
Prior art date
Application number
PL02371264A
Other languages
English (en)
Inventor
Pamela Jean Schofield
Den Berg Henry Van
David Ernest Burgio
Arkadi Aaron Chines
Original Assignee
The Procter & Gamble Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23352430&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL371264(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Procter & Gamble Company filed Critical The Procter & Gamble Company
Publication of PL371264A1 publication Critical patent/PL371264A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL02371264A 2001-12-21 2002-12-16 Sposób leczenia chorób kości PL371264A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34487501P 2001-12-21 2001-12-21

Publications (1)

Publication Number Publication Date
PL371264A1 true PL371264A1 (pl) 2005-06-13

Family

ID=23352430

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02371264A PL371264A1 (pl) 2001-12-21 2002-12-16 Sposób leczenia chorób kości

Country Status (24)

Country Link
US (5) US20030118634A1 (pl)
EP (1) EP1455796A1 (pl)
JP (1) JP2005514400A (pl)
KR (1) KR100638122B1 (pl)
CN (1) CN100479823C (pl)
AR (1) AR038041A1 (pl)
AU (1) AU2002360619B2 (pl)
CA (1) CA2469779C (pl)
CZ (1) CZ2004690A3 (pl)
HK (1) HK1087039A1 (pl)
HU (1) HUP0402267A3 (pl)
IL (2) IL162053A0 (pl)
MA (1) MA27157A1 (pl)
MX (1) MXPA04006027A (pl)
MY (1) MY147886A (pl)
NO (1) NO340249B1 (pl)
NZ (1) NZ532994A (pl)
PE (1) PE20030743A1 (pl)
PL (1) PL371264A1 (pl)
RU (1) RU2294203C2 (pl)
SK (1) SK2532004A3 (pl)
TW (1) TWI349553B (pl)
WO (1) WO2003055496A1 (pl)
ZA (1) ZA200404007B (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003055496A1 (en) * 2001-12-21 2003-07-10 The Procter & Gamble Company Method for the treatment of bone disorders
KR20120065435A (ko) * 2002-05-10 2012-06-20 에프. 호프만-라 로슈 아게 골다공증 치료 및 예방용 비스포스폰산
US20040097468A1 (en) * 2002-11-20 2004-05-20 Wimalawansa Sunil J. Method of treating osteoporosis and other bone disorders with upfront loading of bisphosphonates, and kits for such treatment
BR0309691A (pt) * 2002-12-20 2005-08-02 Hoffmann La Roche Formulação de ibandronato em alta dose
KR20080083068A (ko) * 2004-05-24 2008-09-12 더 프록터 앤드 갬블 캄파니 킬레이팅제를 함유하는 비스포스포네이트의 고형의 장용 경구 투여 형태
WO2006020009A1 (en) * 2004-07-23 2006-02-23 The Procter & Gamble Company Solid oral dosage form of a bisphosphonate containing a chelating agent
US20070191315A1 (en) * 2006-02-16 2007-08-16 Bengt Bergstrom Method for administering ibandronate

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA777769A (en) * 1963-03-18 1968-02-06 H. Roy Clarence Substituted methylene diphosphonic acid compounds and detergent compositions
DE2405254C2 (de) * 1974-02-04 1982-05-27 Henkel KGaA, 4000 Düsseldorf Verwendung von 3-Amino-1-Hydroxypropan-1, 1-diphosphonsäure oder ihrer wasserlöslichen Salze bei der Beeinflußung von Calciumstoffwechselstörungen im menschlichen oder tierischen Körper
DE2534391C2 (de) * 1975-08-01 1983-01-13 Henkel KGaA, 4000 Düsseldorf 1-Hydroxy-3-aminoalkan-1,1-diphosphonsäuren
DE2745083C2 (de) * 1977-10-07 1985-05-02 Henkel KGaA, 4000 Düsseldorf Hydroxydiphosphonsäuren und Verfahren zu deren Herstellung
US4252742A (en) * 1979-07-13 1981-02-24 Ciba-Geigy Corporation Chemical process for the preparation of 2,6-dialkylcyclohexylamines from 2,6-dialkylphenols
DE2943498C2 (de) * 1979-10-27 1983-01-27 Henkel KGaA, 4000 Düsseldorf Verfahren zur Herstellung von 3-Amino-1-hydroxypropan-1,1-diphosphonsäure
DE3016289A1 (de) * 1980-04-28 1981-10-29 Henkel KGaA, 4000 Düsseldorf Verfahren zur herstellung von omega -amino-1-hydroxyalkyliden-1,1-bis-phosphonsaeuren
IT1201087B (it) * 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
FR2531088B1 (fr) * 1982-07-29 1987-08-28 Sanofi Sa Produits anti-inflammatoires derives de l'acide methylenediphosphonique et leur procede de preparation
DE3434667A1 (de) * 1984-09-21 1986-04-03 Henkel KGaA, 4000 Düsseldorf 4-dimethylamino-1-hydroxybutan-1,1-diphosphonsaeure, deren wasserloesliche salze, verfahren zu ihrer herstellung sowie ihre verwendung
IT1196315B (it) * 1984-10-29 1988-11-16 Gentili Ist Spa Procedimento per la preparazione di acidi difosfonici
IL77243A (en) * 1984-12-21 1996-11-14 Procter & Gamble Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds
US4812311A (en) * 1984-12-21 1989-03-14 The Procter & Gamble Company Kit for use in the treatment of osteoporosis
DE3512536A1 (de) * 1985-04-06 1986-10-16 Boehringer Mannheim Gmbh, 6800 Mannheim Neue diphosphonsaeure-derivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US4761406A (en) * 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
DE3540150A1 (de) * 1985-11-13 1987-05-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3623397A1 (de) * 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3626058A1 (de) * 1986-08-01 1988-02-11 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3640938A1 (de) * 1986-11-29 1988-06-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindung enthaltende arzneimittel
CA1339805C (en) * 1988-01-20 1998-04-07 Yasuo Isomura (cycloalkylamino)methylenebis(phosphonic acid) and medicines containing the same as an active
EP0333082A3 (en) * 1988-03-15 1991-05-02 Takeda Chemical Industries, Ltd. Cephem compounds, their production and use
GB2217988B (en) * 1988-04-11 1992-04-01 Gould Leonard W Regimen for increasing bone density in humans
DE3822650A1 (de) * 1988-07-05 1990-02-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US5018651A (en) * 1988-12-27 1991-05-28 Hull Harold L Side or end dump article carrier
DE3917153A1 (de) * 1989-05-26 1990-11-29 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US4922007A (en) * 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
NL8902727A (nl) * 1989-11-06 1991-06-03 Philips Nv Objecthouder voor ondersteuning van een object in een geladen deeltjesbundelsysteem.
US5356887A (en) * 1990-01-31 1994-10-18 Merck & Co., Inc. Pharmaceutical compositions containing insoluble calcium salts of amino-hydroxybutylidene bisphoshonic acids
US5019651A (en) * 1990-06-20 1991-05-28 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
TW237386B (pl) * 1992-04-15 1995-01-01 Ciba Geigy
CZ297094A3 (en) * 1992-05-29 1995-12-13 Procter & Gamble Pharma Phosphate compounds containing quaternary nitrogen, their use and pharmaceutical compositions containing thereof
US5391743A (en) * 1992-05-29 1995-02-21 Procter & Gamble Pharmaceuticals, Inc. Quaternary nitrogen-containing phosphonate compounds, pharmaceutical compositions, and methods of treating abnormal calcium and phosphate metabolism and methods of treating and preventing dental calculus and plaque
CA2138366C (en) * 1992-06-30 1998-09-22 Kristine Hovancik Methods for the treatment of arthritis using phosphonates and nsaids
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
FR2703590B1 (fr) * 1993-04-05 1995-06-30 Sanofi Elf Utilisation de derives d'acide bisphosphonique pour la preparation de medicaments destines a favoriser la reparation osseuse .
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
US20010007863A1 (en) * 1998-06-18 2001-07-12 Merck & Co., Inc. Wet granulation formulation for bisphosphonic acids
US5462932A (en) * 1994-05-17 1995-10-31 Merck & Co., Inc. Oral liquid alendronate formulations
US6008206A (en) * 1994-09-21 1999-12-28 Merck & Co., Inc. Sodium alendronate preparation for local administration
US20010051616A1 (en) * 1995-02-17 2001-12-13 David B. Karpf Method of lessening the risk of vertebral fractures
EP0832195B1 (de) * 1995-06-07 2005-11-09 co.don Aktiengesellschaft Verfahren zur osteoporosediagnose und zur testung potentieller osteoporose-therapeutika unter verwendung von standardisierten, primären osteoblastenzellkulturen aus osteoporotischen patienten
DE19615812A1 (de) * 1996-04-20 1997-10-23 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation
GB2324726A (en) * 1997-05-01 1998-11-04 Merck & Co Inc Combination Therapy for the Treatment of Osteoporosis
US5994329A (en) * 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
US6432932B1 (en) * 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
US6124314A (en) * 1997-10-10 2000-09-26 Pfizer Inc. Osteoporosis compounds
US6432931B1 (en) * 1998-06-24 2002-08-13 Merck & Co., Inc. Compositions and methods for inhibiting bone resorption
IT1303672B1 (it) * 1998-07-28 2001-02-23 Nicox Sa Sali nitrati di farmaci attivi nei disordini ossei
EP0998932A1 (de) * 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung
EP0998933A1 (de) * 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Verfahren zur Herstellung von bisphosphonathaltigen pharmazeutischen Zusammensetzungen zur oralen Applikation
DE69927048T2 (de) * 1998-12-04 2006-06-08 Roche Diagnostics Gmbh Ibandroinsäure zur förderung der osseointegration der endoprothesen
US6468559B1 (en) * 2000-04-28 2002-10-22 Lipocine, Inc. Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
CN1224423C (zh) * 2000-07-17 2005-10-26 山之内制药株式会社 改善口服吸收的医药组合物
WO2002007733A2 (en) * 2000-07-19 2002-01-31 Eli Lilly And Company Method for enhancing bone mineral density gain by administration of raloxifene
US6638920B2 (en) * 2000-07-21 2003-10-28 Merck & Co., Inc. Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses
ES2243457T3 (es) * 2001-01-23 2005-12-01 Gador S.A. Composicion que comprende bifosfonatos para la prevencion y/o tratamiento de trastornos metabolicos de huesos, procedimiento de preparacion de dicha composicion y usos de la misma.
AR034199A1 (es) * 2001-02-01 2004-02-04 Riderway Corp Composicion farmacologica liquida para el tratamiento de enfermedades oseas y procedimientos para su elaboracion
CN1233325C (zh) * 2001-02-06 2005-12-28 罗亚尔·亚历山德拉儿童医院 治疗骨坏死和处理有发展为骨坏死危险的患者用的药物
MXPA03007837A (es) * 2001-03-01 2004-03-16 Emisphere Techonologies Inc Composiciones para suministrar bisfosfonatos.
AU2002305359B2 (en) * 2001-05-10 2005-05-26 Merck & Co., Inc. Estrogen receptor modulators
US20030139378A1 (en) * 2001-12-13 2003-07-24 Daifotis Anastasia G. Liquid bisphosphonate formulations for bone disorders
WO2003055496A1 (en) * 2001-12-21 2003-07-10 The Procter & Gamble Company Method for the treatment of bone disorders
US20050070504A1 (en) * 2001-12-21 2005-03-31 The Procter & Gamble Co. Risedronate compositions and their methods of use
US7488496B2 (en) * 2002-03-06 2009-02-10 Christer Rosen Effervescent compositions comprising bisphosphonates and methods related thereto
WO2003086415A1 (en) * 2002-04-05 2003-10-23 Merck & Co., Inc. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
KR20120065435A (ko) * 2002-05-10 2012-06-20 에프. 호프만-라 로슈 아게 골다공증 치료 및 예방용 비스포스폰산
US20040188316A1 (en) * 2003-03-26 2004-09-30 The Procter & Gamble Company Kit for pharmaceutical use

Also Published As

Publication number Publication date
TWI349553B (en) 2011-10-01
JP2005514400A (ja) 2005-05-19
KR20040065283A (ko) 2004-07-21
AU2002360619B2 (en) 2006-10-05
CN100479823C (zh) 2009-04-22
IL162053A0 (en) 2005-11-20
US20080214505A1 (en) 2008-09-04
SK2532004A3 (en) 2004-11-03
EP1455796A1 (en) 2004-09-15
HK1087039A1 (en) 2006-10-06
MXPA04006027A (es) 2004-09-27
RU2294203C2 (ru) 2007-02-27
US20080260827A1 (en) 2008-10-23
CA2469779C (en) 2008-02-12
HUP0402267A2 (hu) 2005-02-28
CA2469779A1 (en) 2003-07-10
NO340249B1 (no) 2017-03-27
MA27157A1 (fr) 2005-01-03
IL162053A (en) 2009-09-22
CN1723024A (zh) 2006-01-18
NO20043113L (no) 2004-09-01
TW200301704A (en) 2003-07-16
KR100638122B1 (ko) 2006-10-24
CZ2004690A3 (cs) 2004-09-15
NZ532994A (en) 2008-05-30
PE20030743A1 (es) 2003-10-22
ZA200404007B (en) 2005-07-27
MY147886A (en) 2013-01-31
RU2004122433A (ru) 2005-03-10
HUP0402267A3 (en) 2007-05-29
US20030118634A1 (en) 2003-06-26
AR038041A1 (es) 2004-12-22
WO2003055496A1 (en) 2003-07-10
AU2002360619A1 (en) 2003-07-15
US20080261924A1 (en) 2008-10-23
US20070166237A1 (en) 2007-07-19

Similar Documents

Publication Publication Date Title
TW200603816A (en) Risedronate compositions and their methods of use
ATE375341T1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
GR3033127T3 (en) Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
IL160028A (en) Thiophene carboxamide derivatives, process for their preparation, pharmaceutical compositions comprising them and their use in therapy
GB9408577D0 (en) New compound
HUP0203325A2 (hu) Biciklusos aminosavak, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
RU95102778A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования потерь костной ткани и снижения уровня холестерина в сыворотке, фармацевтический препарат, содержащий 2-фенил-3-ароилбензотиофен
CA2219115A1 (en) N-benzyl-3-indoleacetic acids as cyclooxygenase-2-inhibitors and antiinflammatory drugs
TW200744673A (en) Improved ibandronate formulations
PT1326613E (pt) Utilizacao de derivados de imidazo[1,2-a]piridin-,imidazo[1,2-a]pirimidin- e imidazo[1,2-a]pirazin-3-il-amina substituidos para a fabricacao de medicamentos para inibicao de nos
BG104476A (en) Therapeutical form for tolterodin with controlled release
SE9901573D0 (sv) New compounds
HK1087039A1 (en) Use of biphosphonate in preparing medical kit and a kit used for increasing bone mass
GB0130677D0 (en) Medicaments and novel compounds
CA2211320A1 (en) 5-methanesulfonamido-3h-isobenzofuran-1-ones as inhibitors of cyclooxygenase-2
GB2331926A (en) Pharmaceutical compositions containing ibuprofen and domperidone for the treatment of migraine
MY160429A (en) 2, 5-disubstituted 3-mercaptopentanoic acid
WO2000066550A8 (en) New compounds
DE60306503D1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
CA2301590A1 (en) 2-aminopyridines as inhibitors of cyclooxygenase-2
ATE441653T1 (de) Phosphorenthaltende verbindugnen mit antithrombitische wirkung
DE69434002D1 (de) 2,3 diaryl-1-benzopyrame zur behandlung von dermatitis
HUP0300043A2 (en) Method and composition for the treatment of pain
CA2252401A1 (en) Pyridinyl-2-cyclopenten-1-ones as selective cyclooxygenase-2 inhibitors
GEP20043356B (en) Compounds Useful For Treatment or Prevention of Diseases Mediated By Alpha- 2B-Adrenoceptor

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)